Skip to content
ppharmaranks
Menu

Best Angiotensin Converting Enzyme Inhibitor for ventricular dysfunction, left

Top-rated pick: Qbrelis — pharmaranks score 70/100, the highest of the 3 Angiotensin Converting Enzyme Inhibitor drugs used for ventricular dysfunction, left, ranked by our independent FDA recall-safety score. Compare them with all treatments for ventricular dysfunction, left or the full Angiotensin Converting Enzyme Inhibitor class. Not medical advice — always consult a professional.

Quick answer: Of the 3 angiotensin converting enzyme inhibitor drugs we rate for ventricular dysfunction, left, 2 are available as lower-cost generics, and most are tablet. Our ranking reflects each drug’s FDA recall-safety record — not clinical effectiveness for ventricular dysfunction, left; the right choice depends on your situation, so confirm it with your prescriber.

Rated against independent regulatory sources·Last updated August 15, 2026·How we rate

Other drug classes for ventricular dysfunction, left

Top angiotensin converting enzyme inhibitor for ventricular dysfunction, left: 1. Qbrelis · 2. Lotensin · 3. Quinapril Hydrochloride

Best-rated Angiotensin Converting Enzyme Inhibitor for ventricular dysfunction, left, ranked by pharmaranks score
#DrugRatingPharmacy pays
170/100$1View →
2Not yet rated$2View →
3Not yet ratedView →

Full ranking · 3 drugs

Frequently asked

What is the best angiotensin converting enzyme inhibitor for ventricular dysfunction, left?
By our independent recall-safety rating — not an efficacy measure — qbrelis ranks highest among Angiotensin Converting Enzyme Inhibitor drugs used for ventricular dysfunction, left. Always consult a professional.
Which angiotensin converting enzyme inhibitor drugs treat ventricular dysfunction, left?
pharmaranks lists 3 Angiotensin Converting Enzyme Inhibitor products used for ventricular dysfunction, left, per NIH RxClass drug-classification data — each independently rated and ranked above.
How are these ranked?
By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.